Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 76

Guselkumab demonstrates superior efficacy in clinical trials, offering new hope to Crohn’s disease patients

In a major advance for patients with Crohn’s disease, a new study led by researchers at Mount Sinai Health System found that guselkumab, a medication with a mechanism of action that is new to inflammatory bowel disease (IBD) treatment, outperformed an established standard of care in promoting intestinal healing and symptom relief.

These findings from two pivotal Phase III known as GALAXI 2 and 3, published in The Lancet, provided the basis for the recent Food and Drug Administration approval of guselkumab (brand name Tremfya) for the treatment of moderately to severely active Crohn’s disease.

Crohn’s disease affects roughly 780,000 people in the United States and often requires a lifetime of management. Despite numerous available biologic medications, many patients fail to achieve sustained remission. Guselkumab blocks the interleukin-23 (IL-23) pathway, a key driver of chronic intestinal inflammation.

What ever-growing incisors can teach us about genetic disease

Teeth may seem like static fixtures, but a new collaboration between engineers and clinicians is proving just how dynamic, informative and medically significant our teeth can be.

In a study, published in ACS Applied Materials & Interfaces, engineers and dentists come together to uncover how teeth, as , hold key information for understanding rare craniofacial disorders that develop during childhood.

Kyle Vining, Assistant Professor in Materials Science and Engineering (MSE) and in Preventive and Restorative Science at Penn Dental Medicine, leads this interdisciplinary team, which includes Yuchen (Tracy) Jiang, a former master’s student in MSE, Kei Katsura, a pediatric dentist and KL2 postdoctoral research scholar at Children’s Hospital of Philadelphia (CHOP) and the Institute of Translational Medicine and Therapeutics at Penn, and Elizabeth Bhoj, Assistant Professor of Pediatrics in Penn Medicine and the Division of Human Genetics at CHOP.

Gene essential for vitamin D absorption could help unlock treatments for cancer and autoimmune diseases

Vitamin D is not only an essential nutrient, but also the precursor of the hormone calcitriol, indispensable for health. It regulates the uptake of phosphate and calcium necessary for bones by the intestines, as well as cell growth and the proper function of muscles, nerve cells, and the immune system.

Now, researchers have shown for the first time in Frontiers in Endocrinology that a particular gene called SDR42E1 is crucial for taking up vitamin D from the gut and further metabolizing it—a discovery with many possible applications in precision medicine, including .

“Here we show that blocking or inhibiting SDR42E1 may selectively stop the growth of cancer cells,” said Dr. Georges Nemer, a professor and associate dean for research at the University College of Health and Life Sciences at Hamad Bin Khalifa University in Qatar, and the study’s corresponding author.

Gene editing offers transformative solution to saving endangered species

Gene editing technologies—such as those used in agriculture and de-extinction projects—can be repurposed to offer what an international team of scientists is calling a transformative solution for restoring genetic diversity and saving endangered species.

Iron oxide behavior under pressure may reduce reliance on rare-earth metals in consumer, energy and medical tech

Researchers at The University of Texas at Arlington have discovered a surprising new type of magnetic property that could lead to stronger magnets made from tiny particles of common iron oxide. This finding could enhance the performance of everyday technologies while reducing the need for rare-earth metals—materials that are more costly, less sustainable and harder to obtain.

Expanding the material design space at the nanoscale

Researchers are creating new moiré materials at the nanometer scale using advanced DNA nanotechnology. DNA moiré superlattices form when two periodic DNA lattices are overlaid with a slight rotational twist or positional offset. This creates a new, larger interference pattern with completely different physical properties.

Study sheds light on how inherited cancer mutations drive tumor growth

Most cancer genome studies have focused on mutations in the tumor itself and how such gene variants allow a tumor to grow unchecked. A new study, led by researchers at Washington University School of Medicine in St. Louis, takes a deep dive into inherited cancer mutations measured in a healthy blood sample and reports how those mutations might take a toll on the body’s cells starting at birth, perhaps predisposing a person to develop cancers at various stages of life.

The authors analyzed the inherited genomes of more than 1,000 cancer patients and determined how inherited mutations — also known as germline variants — result in malfunctioning proteins, which in turn can impair physiological activities. The findings have implications for determining an individual’s inherited cancer risk and informing potential new strategies for prevention, early detection and treatment.

The study appears April 14 in the journal Cell.

Findings could help predict cancer risk over a person’s lifetime, develop prevention strategies.

Landmark study investigates potential of Ambroxol, a cough medicine, to slow Parkinson’s-related dementia

LONDON, Ont. – Dementia poses a major health challenge with no safe, affordable treatments to slow its progression.

Researchers at Lawson Research Institute (Lawson), the research arm of St. Joseph’s Health Care London, are investigating whether Ambroxol — a cough medicine used safely for decades in Europe — can slow dementia in people with Parkinson’s disease.

Published today in the prestigious JAMA Neurology, this 12-month clinical trial involving 55 participants with Parkinson’s disease dementia (PDD) monitored memory, psychiatric symptoms and GFAP, a blood marker linked to brain damage.

Parkinson’s disease dementia causes memory loss, confusion, hallucinations and mood changes. About half of those diagnosed with Parkinson’s develop dementia within 10 years, profoundly affecting patients, families and the health care system.

/* */